BR112016029820A2 - tratamento de doença renal crônica e outras disfunções renais usando um modulador de gdf15 - Google Patents

tratamento de doença renal crônica e outras disfunções renais usando um modulador de gdf15

Info

Publication number
BR112016029820A2
BR112016029820A2 BR112016029820A BR112016029820A BR112016029820A2 BR 112016029820 A2 BR112016029820 A2 BR 112016029820A2 BR 112016029820 A BR112016029820 A BR 112016029820A BR 112016029820 A BR112016029820 A BR 112016029820A BR 112016029820 A2 BR112016029820 A2 BR 112016029820A2
Authority
BR
Brazil
Prior art keywords
kidney
kidney disease
treatment
chronic kidney
renal dysfunction
Prior art date
Application number
BR112016029820A
Other languages
English (en)
Inventor
Gyuris Jeno
Lerner Lorena
Original Assignee
Aveo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals Inc filed Critical Aveo Pharmaceuticals Inc
Publication of BR112016029820A2 publication Critical patent/BR112016029820A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a invenção oferece métodos e composições para tratar um indivíduo tendo um distúrbio renal, tal como doença renal crônica (ckd), insuficiência renal em estágio terminal, diabetes, resistência à insulina, hipertrofia do rim, hipotrofia do rim, doença renal policística, proteinúria, hiperglicemia, hiperuricemia, gota, cálculo renal, hipertensão ou nefropatia hipertensiva, dislipidemia, anemia e/ou produção reduzida de eritropoietina, deficiência em ferro ou hiperfiltração. os métodos e composição usam ou contêm uma composição que reduz ou inibe a atividade de gdf15.
BR112016029820A 2014-06-20 2015-06-19 tratamento de doença renal crônica e outras disfunções renais usando um modulador de gdf15 BR112016029820A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462015242P 2014-06-20 2014-06-20
PCT/US2015/036794 WO2015196145A1 (en) 2014-06-20 2015-06-19 Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator

Publications (1)

Publication Number Publication Date
BR112016029820A2 true BR112016029820A2 (pt) 2017-10-24

Family

ID=53724443

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016029820A BR112016029820A2 (pt) 2014-06-20 2015-06-19 tratamento de doença renal crônica e outras disfunções renais usando um modulador de gdf15

Country Status (9)

Country Link
US (2) US20170137506A1 (pt)
EP (1) EP3157953B1 (pt)
JP (1) JP6768527B2 (pt)
AU (2) AU2015276800B2 (pt)
BR (1) BR112016029820A2 (pt)
CA (1) CA2952032C (pt)
EA (1) EA201790051A1 (pt)
MX (1) MX2016016826A (pt)
WO (1) WO2015196145A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013364133B2 (en) 2012-12-21 2018-10-11 Aveo Pharmaceuticals, Inc. Anti-GDF15 antibodies
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
CA2964808C (en) 2014-10-30 2023-06-27 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells
EP3393494A1 (en) * 2015-12-22 2018-10-31 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
JP6968430B2 (ja) 2016-01-29 2021-11-17 ワシントン・ユニバーシティWashington University 緑内障におけるｇｄｆ１５及びその使用方法
CN109071647B (zh) 2016-04-27 2022-11-22 诺华股份有限公司 抗生长分化因子15的抗体及其用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5733254A (en) 1987-10-15 1998-03-31 Cypress Bioscience, Inc. Method for treating patients suffering from immune thrombocytopenic purpura
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
CA2507749C (en) 1991-12-13 2010-08-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
WO2002088346A2 (en) 2001-05-01 2002-11-07 National Research Council Of Canada A system for inducible expression in eukaryotic cells
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
US7919084B2 (en) 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
SI2441466T1 (sl) * 2004-04-13 2015-01-30 St Vincent's Hospital Sydney Limited Centre For Immunology Sredstvo, ki inhibira MIC-1
AU2008286706B2 (en) * 2007-08-16 2014-03-06 Garvan Institute Of Medical Research Agents and methods for modulating macrophage inhibitory cytokine (MIC-1) activity
CN101951921A (zh) * 2007-09-17 2011-01-19 比奥尼里斯有限责任公司 用于治疗恶病质的方法和手段
US20100266707A1 (en) * 2007-10-09 2010-10-21 Samuel Norbert Breit Method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1
CN102203619B (zh) * 2008-10-31 2015-12-16 圣文森特医院悉尼有限公司 慢性肾病中的预测方法
WO2014049087A1 (en) * 2012-09-26 2014-04-03 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
AU2013364133B2 (en) * 2012-12-21 2018-10-11 Aveo Pharmaceuticals, Inc. Anti-GDF15 antibodies

Also Published As

Publication number Publication date
EA201790051A1 (ru) 2017-04-28
WO2015196145A1 (en) 2015-12-23
AU2015276800B2 (en) 2021-03-04
JP2017519764A (ja) 2017-07-20
EP3157953B1 (en) 2021-12-22
US11897948B2 (en) 2024-02-13
CA2952032C (en) 2023-03-14
EP3157953A1 (en) 2017-04-26
CA2952032A1 (en) 2015-12-23
US20190292252A1 (en) 2019-09-26
US20170137506A1 (en) 2017-05-18
AU2015276800A1 (en) 2017-01-05
JP6768527B2 (ja) 2020-10-14
MX2016016826A (es) 2017-08-28
AU2021203523A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
BR112016029820A2 (pt) tratamento de doença renal crônica e outras disfunções renais usando um modulador de gdf15
BR112017018715A2 (pt) agonista de receptor de angiotensina ii para tratar fibrose pulmonar
DK3440076T3 (da) Heterocykliske amider, der kan anvendes som proteinmodulatorer
EP3438282A4 (en) METHOD FOR SCREENING CANDIDATE SUBSTANCES FOR AN ACTIVE COMPONENT TO PREVENT OR TREAT AT LEAST ONE SELECTED DISEASE IN THE KIDNEY HYPOFUNCTION GROUP, CHRONIC KIDNEY DISEASE AND KIDNEY DEFICIENCY
MX2021015631A (es) Moduladores del receptor arilo y metodos para elaborar y usar los mismos.
NZ725568A (en) Modified j-chain
MY197345A (en) Antibody molecules to april and uses thereof
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
BR112016029318A2 (pt) tratamento de mielomas
EP3501527A4 (en) COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDER, CONTAINING A VESICLE DERIVED FROM BACTERIA OF A SPECIES ACTOBACILLUS
BR112016018455A2 (pt) composto, ácido, medicamento, métodos para prevenir ou tratar obesidade e diabetes melito e para inibir uma enteropeptidase, e, uso de um composto.
EA202091598A3 (ru) Процесс контроля уровня содержания гликанов в составе
MX2019000088A (es) Composiciones y metodos para detectar y tratar la diabetes.
EP3433332C0 (en) LIGNIN LIQUID COMPOSITION, LIGNIN BASED RESIN AND METHOD OF INCREASING THE SOLUBILITY OF LIGNIN
IL248129A0 (en) Transfused Heterocyclics as Gpr119 Regulators for the Treatment of Diabetes, Obesity, Dyslipidemia, and Related Disorders
DK3275883T3 (da) Fremgangsmåde til produktion af ny nitrogenholdig forbindelse eller salt deraf, og mellemprodukt deraf
DK3650458T3 (da) Platforme til screening af kemisk kodede, rumligt adresserede biblioteker
EP3381472A4 (en) MEDICINAL PRODUCTS FOR THE TREATMENT OR PREVENTION OF DISTURBANCES CAUSED BY TGF SIGNALS AND USE THEREOF
GB201718766D0 (en) Providing automated securitized funding of deposits, collateral, bonds and/or securities online
DK3972853T3 (da) Sikkerhedsdokument og fremgangsmåde til fremstilling heraf
DK3436553T3 (da) Kompatibiliserende og stabiliserende sammensætning til brændselsolier og fremgangsmåde til stabilisering af olierne
EA201992170A1 (ru) Модуляторы экспрессии pcsk9
SG11202003614WA (en) Method for production of recombinant e. coli asparaginase
BR112019011635A2 (pt) terapia genética para mucopolissacaridose, tipo i
BR112017016833A2 (pt) cartucho eletrolítico, sistemas e métodos de usar o mesmo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]